Back to search

Article

Synthesis and Biological Assessment of Chalcone and Pyrazoline Derivatives as Novel Inhibitor for ELF3-MED23 Interaction

2024-03-05

Abstract excerpt

HER2 overexpression significantly contributes to the aggressive nature and recurrent patterns observed in various solid tumors, notably gastric cancers. Trastuzumab, HER2-targeting monoclonal antibody drug, has shown considerable clinical success, however, readily emerging drug resistance emphasizes the pressing need for improved interventions in HER2-overexpressing cancers. To address this, we proposed targeting...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
08521380-bbd1-555c-9f2d-1cb27d7ca4d5
DOI
10.1101/2024.03.01.583029
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Synthesis and Biological Assessment of Chalcone and Pyrazoline Derivatives as Novel Inhibitor for ELF3-MED23 InteractionDOI 10.1101/2024.03.01.583029
Molecular Pathways: HER3 Targeted TherapySemantic proximity
Estrogen Receptor α/14-3-3 molecular glues as alternative treatment strategy for endocrine resistant breast cancerSemantic proximity
HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity
Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity
HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity
Targeting HER3 for cancer treatment: a new horizon for an old targetSemantic proximity
Exploring target selectivity in designing and identifying PI3Kα inhibitors for triple negative breast cancer with fragment-based and bioisosteric replacement approachSemantic proximity
Understanding the biology of HER3 receptor as a therapeutic target in human cancerSemantic proximity
HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity
Research and Development of a Multi-Target HER2 Inhibitor (CPD 1) and Its Mechanism and Application in Combating HER2-Positive Breast CancerSemantic proximity
Advances in Targeting HER3 as an Anticancer TherapySemantic proximity
Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodiesSemantic proximity
Select a neighboring publication to make it the new centre.